Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) insider Peter Rahmer sold 50,000 shares of Relay Therapeutics stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the transaction, the insider directly owned 225,857 shares in the company, valued at $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Peter Rahmer also recently made the following trade(s):
- On Tuesday, April 28th, Peter Rahmer sold 753 shares of Relay Therapeutics stock. The stock was sold at an average price of $14.79, for a total transaction of $11,136.87.
Relay Therapeutics Trading Up 5.0%
RLAY opened at $18.65 on Friday. The company has a fifty day moving average price of $14.70 and a two-hundred day moving average price of $11.50. Relay Therapeutics, Inc. has a 1-year low of $3.03 and a 1-year high of $19.93. The company has a market cap of $3.57 billion, a P/E ratio of -11.88 and a beta of 1.67.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. Commodore Capital LP bought a new stake in Relay Therapeutics in the second quarter valued at $46,191,000. Perceptive Advisors LLC boosted its position in shares of Relay Therapeutics by 412.3% in the 1st quarter. Perceptive Advisors LLC now owns 9,751,141 shares of the company’s stock worth $97,024,000 after purchasing an additional 7,847,896 shares in the last quarter. Spruce Street Capital LP purchased a new stake in shares of Relay Therapeutics in the fourth quarter worth $25,246,000. EcoR1 Capital LLC bought a new position in Relay Therapeutics in the 1st quarter worth about $18,952,000. Finally, TCG Crossover Management LLC purchased a new stake in shares of Relay Therapeutics during the third quarter valued at approximately $9,450,000. 96.98% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on RLAY. Barclays boosted their price objective on Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Citizens Jmp upped their price target on shares of Relay Therapeutics from $19.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 20th. Oppenheimer raised their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday, April 28th. Wall Street Zen raised shares of Relay Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.30.
Get Our Latest Analysis on RLAY
About Relay Therapeutics
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
Featured Stories
- Five stocks we like better than Relay Therapeutics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
